First-year real-world outcomes of faricimab in clinically significant diabetic macular oedema: a Swiss retina research network report

Macular DiseasesRetinal Diseases

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Tillmann A, Stillenmunkes R, Garweg JG, Cattaneo J, Bartolomeo N, Grimaldi G, Spitznagel T, De Oliveira Figueiredo EC, Ambresin A, Menghini M, Somfai GM, Zweifel S, Fröhlich J, Artemiev D, Ebneter A, Hatz K, Weinberger A, Pfister IB, Schild C, Eandi C, Munk MR, Swiss Retina Research Network

doi: 10.1007/s40123-025-01252-6

Macular Diseases

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Kitay AM, Tillmann A, Pfister I, Schild C, Bonanata M, Heck K, Spitznagel T, Gabathuler F, Bartolomeo N, Magnin S, Löliger J, Munk MR, Menghini M, Hatz K, Somfai GM, Zweifel S, Ambresin A, Eandi CM, Feltgen N, Weinberger A, Garweg JG, Kurz-Levin MM

doi: 10.1007/s40123-026-01344-x

Macular Diseases

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Ophthalmol Ther

Grimaldi G, Bartolomeo N, Garweg JG, Pfister IB, Schild C, Peyla A, Tillmann A, De Oliveira Figueiredo EC, Spitznagel T, Kitay AM, Gabathuler F, Zweifel S, Kurz-Levin MM, Ebneter A, Somfai GM, Eandi CM, Munk MR, Ambresin A, Menghini M

doi: 10.1007/s40123-025-01305-w

Macular Diseases

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Ophthalmol Sci

Spindler J, Artemiev D, Pfister IB, Schild C, Tillmann A, Heck K, Gabathuler F, Ruscitti L, Spitznagel T, Kitsos-Kalyvianakis K, Munk MR, Hatz K, Zweifel SA, Grimaldi G, Somfai GM, Ambresin A, Weinberger A, Eandi CM, Feltgen N, Kitay A, Ebneter A, Garweg JG

doi: 10.1016/j.xops.2026.101087

Macular DiseasesRetinal Diseases

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Sci Rep

Murao F, Yanai R, Kusuhara S, Abe Y, Shimura M, Ohara H, Terasaki H, Sugimoto M, Matsubara H, Hirano Y, Kinoshita T, Tsujinaka H, Seki K, Iwase T, Mitamura Y, J-CREST

doi: 10.1038/s41598-025-20300-6

Macular Diseases

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Ophthalmol Ther

Mhmud H, Vermeulen JP, Tigchelaar-Besling OAM, Verbraak FD, Barthelmes D, Gillies M, Ponsioen TL, Klaver CCW

doi: 10.1007/s40123-025-01178-z

Macular Diseases

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Clin Exp Ophthalmol

Spooner K, Broadhead G, Fraser-Bell S, Hong T, Wong JG, Chang AA

doi: 10.1111/ceo.14559

Macular DiseasesRetinal Diseases

Artificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project

Br J Ophthalmol

Franquesa-Garcia F, Romero-Nuñez B, Martin-Pinardel R, De Zanet S, González-López JJ, Escobar-Barranco JJ, Ruiz-Del-Tiempo MP, Boixadera A, Fonollosa A, Gómez-Benlloch A, Velazquez-Villoria D, Fernández-Vigo JI, Garay-Aramburu G, Parrado-Carrillo A, Castillon L, Gómez Sánchez S, Lavid FJ, Arruabarrena C, Figueras-Roca M, Bernal-Morales C, Ciller C, Zarranz-Ventura J, DIADEMA investigators

doi: 10.1136/bjo-2025-328172

Macular Diseases

One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration

BMC Ophthalmol

Menghini M, Grimaldi G, Paris A, Bachmann LM, Schmid MK

doi: 10.1186/s12886-025-04463-4

Related content

One-Year Outcomes of Faricimab in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

One-Year Real-World Outcomes of Aflibercept 8 mg in Treatment-Naïve Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report

Twelve-Month Outcomes Using Aflibercept 8 mg in Treatment-Naïve and Pretreated Diabetic Macular Edema: A Swiss Retina Research Network Report

Visual outcomes and anatomical biomarkers of Faricimab for diabetic macular edema in the J-CREST real-world comparison of naïve and treated eyes

Real-World 5-Year Outcomes of Age-Related Macular Degeneration with Bevacizumab as First-Line Anti-VEGF

Real-World 10-Year Outcomes of Anti-VEGF Therapy for Neovascular Age-Related Macular Degeneration: A Meta-Analysis

Artificial intelligence-based fluid quantification predicts clinical outcomes in diabetic macular oedema eyes treated with intravitreal dexamethasone implants: DIADEMA project

One-year clinical outcomes of four-dose induction versus immediate treat-and-extend faricimab regimens in pretreated neovascular age-related macular degeneration